Frazier Management’s Immunovant IMVT Stock Holding History

Frazier Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-585,759	Closed	-$4.99M	–	13
2021 Q4	$4.99M	Hold	585,759	–	–	0.38%	39
2021 Q3	$5.09M	Buy	585,759 +331,759	+131%	+$2.99M	0.41%	32
2021 Q2	$2.69M	Sell	254,000 -254,000	-50%	-$3.55M	0.25%	32
2021 Q1	$8.15M	Buy	+508,000	New	+$13.4M	0.65%	24

Other funds holding IMVT

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frazier Management's IMVT Position: Q1 2022 in Review

Frazier Management sold out of Immunovant (IMVT) in Q1 2022, closing a stake of 585,759 shares — an estimated $4.99M sold.

Frazier Management first reported a position in IMVT in Q1 2021 and held it in 4 quarters. The position peaked at $8.15M in Q1 2021. 112 funds tracked by Wall St. Rank hold IMVT as of Q1 2022.

Frazier Management reported no remaining Immunovant position as of Q1 2022 after selling out during the quarter.
Frazier Management sold 585,759 Immunovant shares in Q1 2022, an estimated $4.99M.
Frazier Management first reported a position in Immunovant in Q1 2021 and held it in 4 quarters.
Frazier Management's Immunovant position peaked at $8.15M in Q1 2021.
112 funds tracked by Wall St. Rank held Immunovant as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.